About Chronic Granulomatous Disease
Chronic Granulomatous Disease is caused by mutations in components of the NADPH oxidase complex, resulting in failure of phagocytes to generate the oxidative burst needed to kill catalase-positive bacteria and fungi, leaving patients susceptible to a characteristic spectrum of life-threatening infections and granulomatous inflammation. The X-linked form caused by CYBB mutations accounts for approximately 65-70% of cases and generally presents earlier and more severely than autosomal recessive variants. Allogeneic hematopoietic stem cell transplantation is the standard curative approach, and gene therapy with lentiviral vectors has demonstrated promise in trials for patients without suitable donors.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Chronic Granulomatous Disease trials.
DHR flow cytometry or nitroblue tetrazolium (NBT) test confirming NADPH oxidase deficiency is required for all trials; CYBB mutation confirmation is additionally required for X-linked specific gene therapy trials
Active invasive fungal infection (Aspergillus, Candida) typically excludes from transplant conditioning studies until infection is controlled; provide current antifungal therapy details
Prophylactic antibiotic and antifungal regimen history (itraconazole, trimethoprim-sulfamethoxazole) should be documented, as protocol-specified prophylaxis changes during trial participation are common
Patient Resources
Find recruiting Chronic Granulomatous Disease trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Chronic Granulomatous Disease. Updated daily.